4Julius S,Kjeldsen S,Weber M,et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsatant or amlodipine:the VALUE randomized trial[J].Lancet,2004,363 (9426):2022 -2031.
5Yui Y,Sumiyoshi T.Kodama K,et al.Comparison of nifedip inere-tard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease:the Japan M ulti center Investigation for Cardiovascular DiseasesB (JM ICB)randomized trial[J].Hypertens Res,2004,27(3):181-191.
6Nissen SE,Tuzcu EM,Libby P,et al.Effect of antihypertensive a gents On cardiovascular events in patients with coronary diseaseand normal blood pressure.The CAM ELOT study:a randomized controlled trial[J].JAMA,2004,292(18):2217-2225.
7Stillberger C,Lany J,Bralnin M,et al.Angiotensin converting enzyme inhibitors and Stroke prevention:what about the influence of atrial fibrillation and antithrombotic therapy[J].Stroke,2003,34 (11):e208.
8Chobanian AV,Bakris GL,Black HK.The seventh Report of the Join National Committeeon Prevention Detection,Evaluation,and Treatmentof High Blood Pressure;the JNC7 report[J].JAMA,2003,289(19):2560-2572.
9Filigheddu F,Troffa C,Glorioso N.Pharmacogenomics of essential hypertension:are we going the right way[J].CardiovascHematol A gents Med Chem,2006,4(1):7-15.
10Arnett DK,Claas SA,Glasser SP.Pharmacogenetics of antihypertensive treatment[J].Vascul Pharmacol,2006,44(1):107-118.
